Nicorette Inhaler — Competitive Intelligence Brief

Nicorette Inhaler (Nicorette Inhaler) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT). Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

Nicorette Inhaler (Nicorette Inhaler) — Ottawa Heart Institute Research Corporation. Nicorette Inhaler delivers nicotine through inhalation to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicorette Inhaler TARGET	Nicorette Inhaler	Ottawa Heart Institute Research Corporation	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicotine gum (C)	Nicotine gum (C)	22nd Century Group, Inc.	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
nicotine nasal spray	nicotine nasal spray	Heinrich-Heine University, Duesseldorf	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Placebo/Galantamine (Reminyl®)	Placebo/Galantamine (Reminyl®)	Ludwig-Maximilians - University of Munich	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Nicoderm C-Q Transdermal Product	Nicoderm C-Q Transdermal Product	University of Miami	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicoderm Transdermal Patch	Nicoderm Transdermal Patch	University of Pennsylvania	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Nicoderm patch first, then Aveva patch	Nicoderm patch first, then Aveva patch	University of Maryland, Baltimore	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy (NRT) class)

1. University of Wisconsin, Madison · 4 drugs in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. The Scripps Research Institute · 1 drug in this class
4. US Department of Veterans Affairs · 1 drug in this class
5. Chrono Therapeutics, Inc. · 1 drug in this class
6. University of Chicago · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Miami · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class